Chamath Palihapitiya-backed Clover Health gets notice of SEC investigation

Health, Fitness & Food

Chamath Palihapitiya

Olivia Michael | CNBC

Chamath Palihapitiya-backed Clover Health Investments said Friday it received a notice of investigation from the Securities and Exchange Commission and that it intends to cooperate.

Clover, however, pushed back against a critical report from short-selling specialist Hindenburg Research, saying some claims in the report were “completely untrue.”

On Thursday, Hindenburg published a scathing report, the title of which called Clover Health a “broken business,” sending the insurance firm’s shares down more than 10%, their biggest daily percentage drop in four months.

Hindenburg also said Clover was under investigation from the Department of Justice and the investigation was not disclosed to investors. In its response to the Hindenburg report on Friday, Clover said it has received inquiries from the DOJ, but did not believe the inquiries were material to its investors. The company characterized the DOJ inquiries as standard practice since Clover works with the Medicare system.

Clover said it decided it did not need to disclose the DOJ inquiries after consultation with its lawyers. The company did not say what the DOJ’s inquiries were about. On the SEC side, Clover said it received the letter from the agency on Thursday following the publication of Hindenburg’s report. The company said it was unware of any investigations outside of the letter from the SEC it received Thursday.

The DOJ on Thursday declined to comment on any potential investigations or inquiries related to Clover.

–Reuters contributed to this report.

This story is developing.

Products You May Like

Articles You May Like

Worries of being a patient advocate
‘An Arm and a Leg’: Revisiting insulin: How the medicine got so expensive
When a Doctor Breaks His Hippocratic Oath, by Suicide
New tool identifies security and privacy risks associated with COVID-19 contact tracing apps
FDA Approves Amondys 45 (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45

Leave a Reply

Your email address will not be published. Required fields are marked *